Probiotics alleviate the extent and severity of atopic dermatitis (AD) in young children, according to the findings of investigators in Australia, who conducted a study of 53 children between 6 and 18 months old who had moderate or severe AD. The infants were given the probiotic Lactobacillus fermentum or an equivalent amount of placebo twice daily for eight weeks.
Clinical assessment was conducted at two, four, and eight weeks (the end of the intervention), with a final assessment at week 16. At the beginning of the study, most participants had used a topical corticosteroid; more than half had been exposed to antibiotics; and about half ate yogurt regularly. Most had been breastfed and had at least one parent with a history of allergy. An allergic reaction to food was reported in almost one third of the children.
By week 16, the extent and severity of AD had improved in significantly more children who received probiotics than in those who received placebo-92% vs 63%. Furthermore, at the completion of the study, 54% of the probiotic group had only mild AD compared with 30% of the placebo group. In addition, as reported by parents, far fewer children in the probiotic group than in the placebo group experienced a lower respiratory tract infection.
Commentary An accompanying editorial by Simon Murch, MD, notes that "probiotics ...continue their impressive march from the fringes of scientific propriety to potential mainstream therapy." This article is another step in that march. Routine use of probiotics will one day be standard practice in pediatrics.
Recognize & Refer: Hemangiomas in pediatrics
July 17th 2019Contemporary Pediatrics sits down exclusively with Sheila Fallon Friedlander, MD, a professor dermatology and pediatrics, to discuss the one key condition for which she believes community pediatricians should be especially aware-hemangiomas.
Pz-cel granted FDA Priority Review to treat recessive dystrophic epidermolysis bullosa
November 28th 2023The FDA granted Priority Review to pz-cel following a phase 1/2 and a pivotal phase 3 study in which the treatment for recessive dystrophic epidermolysis bullosa (RDEB) demonstrated wound healing and pain reduction.
Worsening severity of AD in children associated with increased comorbidity onset risk
November 27th 2023Of patients in the atopic dermatitis (AD) cohort, 36.6% developed at least 1 comorbidity amid follow-up compared to 28.5% in the non-AD reference cohort, investigators of a Sweden, nationwide, population-based cohort study found.
IDP-126 topical gel approved by FDA to treat acne in patients 12 years and up
October 21st 2023The topical gel is the first and only FDA-approved triple-combination, fixed-dose topical treatment for acne, and is set to be available in the first quarter of 2024, according to Bausch Health Companies Inc.